Lakeshore Biopharma (NASDAQ: YSBPW) reviews new buyout proposal

Rhea-AI Filing Summary

LakeShore Biopharma Co., Ltd. filed a report noting that it received a revised preliminary, non-binding proposal to acquire the company. This kind of proposal is an early-stage takeover interest rather than a finalized deal.

The board has formed a special committee to evaluate the proposal. A special committee typically consists of independent directors who review potential transactions and consider what is in the best interests of shareholders before any decision is made.

Positive

• Revised acquisition interest and special committee: LakeShore Biopharma received a revised preliminary, non-binding proposal to acquire the company and formed a special committee, signaling active evaluation of potential strategic alternatives for shareholders.

Negative

• None.

Insights

M&A and corporate governance analyst

LakeShore Biopharma is evaluating a revised, non-binding buyout approach via a special committee.

LakeShore Biopharma has received a revised preliminary, non-binding proposal to acquire the company. Such proposals indicate takeover interest but do not obligate either party to complete a transaction or even reach definitive terms.

The formation of a special committee suggests the board is handling the proposal through independent oversight. This group typically reviews valuation, strategic alternatives, and fairness to shareholders, and may seek outside advisors, before recommending whether to pursue or reject any potential deal.

The outcome depends on negotiations and due diligence that are not described here. Future company communications would be expected to clarify whether discussions advance to a binding agreement or are terminated without a transaction.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

Commission file number: 001-41598

LAKESHORE BIOPHARMA CO., LTD

(Exact name of registrant as specified in its charter)

Building No. 2, 38 Yongda Road

Daxing Biomedical Industry Park

Daxing District, Beijing, PRC

Tel: 010-89202086

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F  ☒          Form 40-F  ☐

EXHIBITS

Exhibit No.		Description
99.1		Press Release - LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company and Formation of Special Committee

1

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	LakeShore Biopharma Co., Ltd
	By:	/s/ Rachel Yu
	Name:	Rachel Yu
	Title:	Director and Chief Financial Officer

Date: August 28, 2025

2

FAQ

What did LakeShore Biopharma (YSBPW) disclose in this 6-K filing?

LakeShore Biopharma disclosed that it received a revised preliminary, non-binding proposal to acquire the company. It also reported that a special committee has been formed to evaluate this proposal on behalf of the board and shareholders.

What is the nature of the acquisition proposal for LakeShore Biopharma (YSBPW)?

The proposal is described as a revised preliminary, non-binding offer to acquire LakeShore Biopharma. This means it reflects early-stage interest in a potential transaction, but it does not yet represent a binding agreement or a confirmed deal structure.

How is LakeShore Biopharma (YSBPW) responding to the acquisition proposal?

LakeShore Biopharma has formed a special committee to respond to the revised preliminary, non-binding acquisition proposal. This committee typically consists of independent directors who assess the proposal’s terms, strategic fit, and overall fairness to shareholders before making recommendations.

What is a special committee in the context of LakeShore Biopharma (YSBPW)?

A special committee is a group of directors designated to review significant transactions like takeover proposals. For LakeShore Biopharma, it will independently evaluate the revised preliminary, non-binding acquisition proposal and consider what outcome best serves the company’s shareholders and stakeholders.

Does the acquisition proposal mean LakeShore Biopharma (YSBPW) will be sold?

The filing only states that LakeShore Biopharma received a revised preliminary, non-binding proposal and formed a special committee. This does not guarantee a sale; it indicates that the company is reviewing potential terms before deciding whether to pursue a definitive transaction.

Where can investors find more details on LakeShore Biopharma’s (YSBPW) proposal?

The 6-K lists a press release as an exhibit titled “LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company and Formation of Special Committee.” That accompanying press release should provide additional details beyond the brief summary description.